86

DAFTAR PUSTAKA

1. Jarvis TR, Chughtai B, Kaplan SA. Bladder Outlet Obstruction and BPH.

Current Bladder Dysfunction Reports.2014;9(4):372

2. Patel ND, Parsons JK. Epidemiology and Etiology of Benign Prostatic

Hyperplasia and Bladder Outlet Obstruction. Indian J Urol.2014;30(2):170-

6

3. Sarma AV, Wei JT. Benign prostate hyperplasia and lower urinary tract

symptomp. NEJM 2012. 367 : 248-57

4. Fadlol A, Mochtar CA. Prediksi Volume Prostat pada Penderita Pembesaran

Prostat Jinak. JIBI.2005;33(4):139-45

5. Kurniawati DH. Profil komplikasi pada pasien hiperplasi prostat jinak paska

tindakan TURP di RS DR Sardjito Jogjakarta. Fakultas Kedokteran

Universitas Gajah mada; 2004.

6. Hasbullah B. Angka Kejadian Komplikasi Lambat Pascaoperasi

Prostatektomi Transvesikal dan Reseksi Transuretral pada Pasien

Pembesaran Prostat Jinak. Jurnal Biomedika 2009 1 : 1-5

7. Rachmat BP, Soetojo. Perbedaan kadar PSA dan TGF β-1 terhadap

pemberian kombinasi 5α reduktase inhibitor (dutasteride) dan anti estrogen

(tamoxifen) pada penderita BPH-LUTS. Fakultas Kedokteran Unair

Surabaya; 2006.

8. Lynch M, SriprasadS, Subramonian S, Thompson P. Postoperative

haemorrhage following transurethral resection of the prostate (TURP) and

photoselective vaporisation of the prostate (PVP), Ann R Coll Surg Engl

2010; 92: 555–8

9. Shanmugasundaram R, Singh JC, Kekre NS. Does dutasteride reduce

perioperative blood loss and postoperative complications after transurethral

resection of the prostate?. Uroscan, 23(3) : 334-5

10. Walsh PC, Retik AB. Transurethral surgery.In : Campbell’s urology 7th ed.

WB saunders. Philadelphia, 1998 : 1511-28.

87

11. Foley CL, Bott SR, Kirby RS. An update on the 5 alpha reductase inhibitor.

Timely Top Med Urol 2003 vol 4, Jun 2003

12. Robert G Hahn, Tim Fagerstrom.Blood loss and postoperative complications

associated with transurethral resection of the prostate after pretreatment with

dutasteride. BJU Int 2007. 99 : 587-94

13. Chapple CR. Pharmacological therapy of benign prostatic/lower urinary

tract symptoms:an overview for the practicing clinician. BJU Int 2004 vol 94

: 738-44

14. Andriole G, Bruchovsky N, et al. Dihydrotestosterone and the prostate: The

scientific rationale for 5 α reductase inhibitors in the treatment of benign

prostatic hyperplasia. The Journal of Urol. Vol 172, Oct 2004 : 1399-403

15. Schwarz S, Obermuller-Jevic C Ute, Hellmis Eva, Koch Winfried, Jacobi

Gunther, Biesalaskin Hans-Konrad. Lycopene Inhibits Disease Progression

in Patient with Benign Prostate Hyperplasia. J Nut,2008,138:53-49

16. Rao AV, Agarwal S. Role of Antioxidant Lycopene in Cancer and Heart

Disease. American College of Nutrition. 2002;Vol.19:5;569-3

17. McCance L. Kathryn, Huether. E Sue. The Biology Basic for Disease in

Adults and Children. 2014

18. Barry MJ, Fowler FJ, Bin L, Pitts JC, Harris CJ, Mulley AG. The Natural

History of Patients with Benign Prostatic Hyperplasia as Diagnosed by North

American Urologists. J Urol.1997;157(1):10-4

19. Amalia R. Faktor-Faktor Risiko Terjadinya Pembesaran Prostat Jinak (Studi

kasus di RS dr. Kariadi, RS Roemani dan RSI Sultan Agung Semarang). Tesis

Program Studi Magister Epidemiologi, Program Pasca Sarjana Universitas

Diponegoro; Semarang; 2007. Downloaded from

http://eprints.undip.ac.id/19133/1/Rizki_Amalia.pdf

20. Data Base Sub-Bagian Urologi, SMF Bedah RS Dr. Kariadi, Semarang, 2015

21. Juliao AA, Plata M, Kazzazi A, Bostanci Y, Djavan B. American Urological

Association and European Association of urology guidelines in the

management of benign prostatic hypertrophy.Curr Opin Urol. 2012

Jan;22(1):34-9

88

22. Presti JC. Neoplasm of the prostat gland. In : Tanagho EA, Mc Aninch JW

eds. Smith’s general urology 15th ed. Lange Medical Books/Mc Graw Hill.

New York. 2000 : 399-417

23. Healey JE, Hodge J. Surgical anatomy 2nd ed. B.C. Decker Inc. Philadelphia.

1990 : 216.

24. Carmeliet P, Jain RK. Review article Angiogenesis in cancer and other

disease. Nature.2000;40(6810):249-57

25. Risau W. Mechanism of angiogenesis. Nature 1997;386:671-4

26. Yancopoulos GD, David S, Gale NW, et al. Vascular-spesific growth factors

and blood vessel formation. Nature 2000;407:242-8

27. Rosen LS. Clinical experience with angiogenesis signaling inhibitors : focus

on vascular endothelial growth factor (VEGF) blockers. Cancer Control

2002, 9(2) : 36-44

28. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway

in tumor growth and angiogenesis. Journal of Clinical Oncology. 2005; 23(5)

: 1011-12

29. Haris AL. Angiogenesis for cancer therapy. Lancet 1997, 349,13-5

30. Walsh K, Sherwood RA, Dew TK, Mulvin D. Angiogenic peptides in

prostatic disease, BJU Inter, 1999,84 : 1081-3

31. Pareek G, Shevchuck M, Armenakas NA, Vasjovic L, Hochberg DA,

Bassilote JB, Fracchia JA. The effect of finasteride on the expression of

vascular endothelial growth factor and microvessel density. A possible

mechanism for decreased prostatic bleeding in treated patients, J Urol, 2003,

169 :20-3

32. Chang YS, di Tomaso E, Mc Donald DM et al. Mosaic blood vessel in tumors

: frequency of cancer cells in contact with flowing blood. Proc Natl Acad USA

2000;97 :14608-13

33. Dvorak HF. Tumors : wound that do not heal. Similarities between tumor

stroma generation and wound healing. N Eng J Med 1986;315 : 1650-9

34. Hemlinger G, Netti PA, Lichtenbeld HC, et al. Solid stress inhibits the growth

of multicellular tumor spheroids. Nat Biotechnol 1997;15 : 778-83

89

35. Berger G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev

Cancer 2003;3 : 401-10

36. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9 : 685-

93

37. Brown LF, Guidi AJ, Schnitt SJ, et al. Vascular stroma formation in

carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the

breast. Clin Cancer Res 1999 ; 5 : 1041-56

38. Understanding angiogenesis. The angiogenesis foundation 2000 ;

angio.org/understanding.contentunderstanding.nntn

39. Kamijo T, Yokose T, Hasebe T, Yonou H, Hayashi R, Ebihara S. Image

analysis of microvessel area predicts radiosensitivity in early stage laryngeal

carcinoma treated with radiotherapy. Clinical cancer research. September

2001 ; 7.p.2809-14

40. Rubio L, Burgos JS, Morera C. Morphometric study of tumor angiogenesis

as a new prognostic factor in nasopharyngeal carcinoma patients. Pathology

oncology research. July 2000; vol 6 : p.210-16

41. Cox ME, et al. Acquisition of neuroendocrine characteristics by prostate

tumour cells is reversible : implications for prostate cancer progression.

Cancer Res, 1999;59(15) : 3821-30

42. Borre, M., B. Nerstrom, and J. Overgaard, Association between

immunohistochemical expression of vascular endothelial growth factor

(VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and

outcome in prostate cancer patients subjected to watchful waiting. Clin

Cancer Res, 2000;6(5) : 1882-90

43. Folkman, J., Fundamental concepts of the angiogenic process. Curr Mol

Med, 2003. 3(7): p. 643-51

44. Nagy, J.A., A.M. Dvorak, and H.F. Dvorak, VEGF-A(164/165) and PlGF:

roles in angiogenesis and arteriogenesis. Trends Cardiovasc Med, 2003.

13(5): p. 169-70

90

45. Shigeno, K., et al., Transrectal colour Doppler ultrasonography for

quantifying angiogenesis in prostate cancer. BJU Int, 2003. 91(3): p. 223-6

46. Strohmeyer, D., et al., Vascular endothelial growth factor and its correlation

with angiogenesis and p53 expression in prostate cancer. Prostate, 2000.

45(3): p.216-24

47. Okada, K., et al., Immunohistochemical localization of platelet-derived

endothelial cell growth factor expression and its relation to angiogenesis in

prostate. Urology, 2001. 57(2): p. 376-81

48. Kikuno, N., et al., The role of thymidine phosphorylase (TP) mRNA

expression in angiogenesis of prostate cancer. Anticancer Res, 2003.

23(2B): p. 1305-12

49. Kataoka, A., et al., Expression of thymidine phosphorylase correlates with

microvessel density in prostate cancer. Oncol Rep, 2005. 13(4): p. 597-600

50. Ren B, et al., Regulation of tumor angiogenesis by thrombospondin-

1.Biochim Biophys Acta, 2005

51. Mehta R, et al., Independent association of angiogenesis index with outcome

in prostate cancer. Clin Cancer Res, 2001. 7(1): p. 81-8

52. Grossfeld, G.D., et al., Thrombospondin-1 expression in patients with

pathologic stage T3 prostate cancer undergoing radical

prostatectomy:association with p53 alterations, tumor angiogenesis, and

tumor progression. Urology, 2002. 59(1): p. 97-102

53. Murphy, C., et al., Nonapical and cytoplasmic expression of interleukin-8,

CXCR1, and CXCR2 correlates with cell proliferation and microvessel

density in prostate cancer. Clin Cancer Res, 2005. 11(11): p. 4117-27

54. Matsuhima, H., et al., Correlation between proliferation, apoptosis, and

angiogenesis in prostate carcinoma and their relation to androgen

ablation.Cancer, 1999. 85(8):p.1822-7

55. Kosasih, E. N. dan Kosasih, A. S.2008.Tafsiran Hasil Pemeriksaan

Laboratorium Klinik. Edisi ke-2. 58, 86

91

56. Isbister, James P. dan Pittiglio, D.Harmening, alih bahasa Devy H. Ronaldi.

1999. Hematologi Klinik: pendekatan berorientasi masalah. Jakarta:

Hipokates. 4

57. Depkes RI. 1989. Hematologi. Jakarta: Pusat Pendidikan Tenaga Kerja. 1, 8,

14-5, 24-5, 27

58. Haanen, C.,Wenegar. 1980. Pengantar Ilmu Penyakit Darah. cetakan pertama.

Bandung: Binacipta.3,23

59. Widmann, FK. 1989. Tinjauan Klinis atas Hasil Pemeriksaan Laboratorium.

Edisi ke-9, Jakarta: EGC. 17-19

60. Ikatan Ahli Urologi Indonesia. Pedoman Penatalaksanaan BPH di Indonesia.

Downloaded from : http://www.iaui.or.id/ast/file/bph.pdf

61. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept

of 5 α reductase inhibition in human benign prostatic hyperplasia. Eur Urol

2000: 37:367- 80

62. Steers WD. 5α reductase activity in the prostate. Urology 2001 : 58 (Suppl

6A) :17-24

63. Anderson JB, Roehrborn CG, Schalken JSA, et al. The progression of benign

prostatic hyperplasia:examining the evidence and determining the risk. Eur

Urol 2001; 39:390-9

64. Kaplan SA. 5 α reductase inhibitors:what role study the play?Urology 2001;

(Suppl6 A) : 65-70

65. Cilotti A, Danza G, Serio M. Clinical application of 5 α reductase inhibitors.

J Endrocrinal Invest 2001; 24:199-203

66. Meidan VM, Touitou E. Treatments for androgenic alopecia and alopecia

areata:current options and future prospects. Drugs 2001; 61:53-69

67. Proscar (Finasteride) Prescribing Information, Merck & Co, Inc

68. Avodart (Dutasteride) Precribing Information, Glaxo Smith Kline

69. Wilde MI, Goa KL. Finasteride. An update of its use in the management

ofsymptomatic be nign prostatic hyperplasia. Drugs 1999; 57:557-81

70. Saez C, Gonzales-Baena AC, Japon MA, Giraldez J, Segura DI, Rodriguez-

Vallejo JM, Gonzalez-Esteban J, Miranda G, Torrubia F. Expression of basic

92

fibroblast growth factor and its receptors FGFR1 dan FGFR2 in human

benign prostatic hyperplasia treated with finasteride. The Prostate. 1999 Jul

; 40(2):83-8

71. Chapple CR. Pharmacological therapy of benign prostatic/lower urinary

tract symptoms : an overview for the practicing clinician. BJU Int 2004 vol

94 : 738-44

72. Haggstrom S, Lissbrant IF, Bergh A, Damber J. Testosterone induces

vascular endothelial growth factor synthesis in the ventral prostate in

castrated rats, J Urol, 1999, 161 : 1620-25

73. Puchner PJ, Miller MI,. The effects of finasteride on haematuria associated

with benign prostatic hyperplasia : A preliminary report, J Urol, 1995, 154 :

1779-82

74. Sieber PR, Rommel FM, Huffnagle HW, et al. The treatment of gross

hematuria secondary to prostatic bleeding with finasteride, J Urol, 1998, 159

: 1232-3

75. Hayek OR, Shabsigh A, Kaplan SA, Kiss AJ, Chen M, Burchardt T, et

al.Castration induces acute vasoconstriction of blood vessels in the rat

prostate concomitant with reduction of prostatic nitric oxide synthase

activity, J Urol, 1999, 162 : 1527-31

76. Schwarz S, Obermuller-Jevic C Ute, Hellmis Eva, Koch Winfried, Jacobi

Gunther, Biesalaskin Hans-Konrad. Lycopene Inhibits Disease Progression

in Patient with Benign Prostate Hyperplasia. J Nut,2008,138:53-49

77. Rao AV, Agarwal S. Role of Antioxidant Lycopene in Cancer and Heart

Disease. American College of Nutrition. 2002;Vol.19:5;569-3

78. Storey ML, Forshee RA, Anderson PA, Hein GL. The Relationship Between

Consumption of Tomato Products, Which Contain Lycopene, and Reduction

Risk of Prostate Cancer. Center for food and Nutritional polic. 2003;pp:70-1

79. Basu A, Imrhan V. Tomatoes Versus Lycopene in Oxodative Stress and

Carcinogenesis: Conclusion From Clinical Trials. European journal of

Clinical Nutrition.2006;pp:9-1

93

80. Agarwal S, Rao AV. Tomato Lycopene and its Role in Human Health and

Chronic Disease. CMAJ.2000;162(3):739-44

81. Meln JR, Lian F, Wang XD. Biological Activity of Lycopene

Metabolites:implication for Cancer Prevention. Nutrition

Review.2006;66:683-667

82. Bowen, Phyllis E. Selection of Surrogate Endpoint Boinmarker to Evaluate

the Efficacy of Lycopene/Tomatoes for Prevention/Progression of Prostate

Cancer. J Nut.2005;135:2068-1070

83. Barber J, Barber NJ. Lycopene and Prostate Cancer. Prostate Cancer and

Prostatic Disease.2002;5:12-6

84. Clinton S. K. 1998. Lycopene: Chemistry, biology and implication for

Human health and the disease. Nutr. Rev. 56:35

85. McCance L. Kathryn, Huether. E Sue. The Biology Basic for Disease in

Adults and Children. 2014

86. Ono M, Takeshima M, Nakano S. Mechanism of the Anticancer Effect of

Lycopene (Tetraterpenoids). The Enzymes. Volume 37;2015:p.146-7

87. Mein J.R, Lian F, Wang X.D. Biological activity of lycopene metabolites:

implica-tions for cancer prevention, Nutr. Rev. 66 (12) (2008) 667–83

88. C.H. Heldin, Targeting the PDGF signaling pathway in tumor treatment, Cell

Commun. Signal. 11 (2013) 97

89. W. Li, et al., Mechanism of human dermal fibroblast migration driven by type

I collagen and platelet-derived growth factor-BB, Mol. Biol. Cell 15 (1)

(2004) 294–309

90. Obermuller-Jevic, U. C., E. Olano-Martin, A. M.Corbacho, et al. Lycopene

inhibits the growth of normal human prostate epithelial cellsin vitro. J. Nutr.

2003;133:3356–60

91. Nahum, A., Hirsch, K., Danilenko, M., Watts, C.K., Prall, O. W., Levy, J. &

Sharoni, Y. Lycopene inhibition of cell cycle progression in breast and

endometrial cancer cells is associated with reduction in cyclin D levels and

94

retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene. 2001;20:

3428–36

92. Foster, J.S., D.C. Henley, S. Ahamed, J.Wimalasena. Esterogen and Cell

Cycle Regulation in Breast Cancer. Trend in Endocrinology and Metabolism.

2001;12 (7): 320-7

93. Febriansah R, Indriyani L, Palupi KD, Ikawati M. TOMAT (Solanum

lycopersicumL.) SEBAGAI AGEN KEMOPREVENTIF POTENSIAL.

2008. URL: https://www.researchgate.net/publication/237534133

94. Walsh PC, Retik AB. Transurethral Surgery. In : Walsh PC, Retik AB,

Vaughan ED Jr, Wein A (Eds); Campbell’s Urology 7th Ed. WB Saunders.

Philadelphia, 1998:1511-28

95. Paetau I, Khachik F, Brown ED, et al. Chronic ingestion of lycopene-rich

tomato juice or lycopene supplements significantly increases plasma

concentrations of lycopene and related tomato carotenoids in humans. Am J

Clin Nutr. 1998;68(6):1187-1195

96. Paetau I, Rao D, Wiley ER, Brown ED, Clevidence BA. Carotenoids in

human buccal mucosa cells after 4 wk of supplementation with tomato juice

or lycopene supplements. Am J Clin Nutr. 1999;70(4):490-494

97. Kucuk O, Sakar FH, Sakr W, et al. Phase II randomized clinical trial of

lycopene supplementation before radical prostatectomy. Cancer Epidermiol

Biomarkers Prev. 2001;10(8):861-868

98. Corridan BM, O’Donoghue M, Hughes DA, Morrissey PA. Low-dose

supplementation with lycopene or beta-carotene does not enhance cell-

mediated immunity in healthy free-living elderly humans. Eur J Clin Nutr.

2001;55(8):627-635

99. Wright AJ, Hughes DA, Bailey AL, Southon S. Beta-carotene and lycopene,

but not lutein, supplementation changes the plasma fatty acid profile of

healthy male non-smokers. J Lab Clin Med. 1999;134(6):592-598

95

100. Rao AV, Agarwal S. Effect of diet and smoking on serum lycopene and lipid

peroxidation. Nutr Res 1998a;18(4):713-21.

101. Rao AV, Agarwal S. Role of antioxidant lycopene in cancer and heart

disease. J Am Coll Nutr 2000;19(5):563-9.

96

Lampiran 1. Tabulasi Data Penelitian

97

Lampiran 2. Dokumentasi Penelitian

Reagen Pewarnaan

Reagen antibody CD 34

Operasi TURP

98

Pengecatan Imunohistokimia CD 34 Pengecatan

Imunohistokimia CD 34

99

Lampiran 3. Hasil Pengecatan Imunohistokimia MVD (CD34)

Kelompok Kontrol (K)

Kelompok Perlakuan (P)

100

Lampiran 5. Ethical Clearance

101

Lampiran 6. Surat Izin Penelitian RSUP Dr. Kariadi Semarang